A key determinant of the success of a biomaterial implant is its interactions with the host immune system, which often determines whether the biomaterial will survive and/or provide any benefit to the host. Every biomaterial implantation initiates a wound environment of varying intensity and activation of host immunity is dependent on leukocyte stimulation via pattern recognition receptors (PRRs) on the cell surface. PRRs recognize both foreign pathogen-associated molecular patterns (PAMPs) that are common on microorganisms (signaling infection) and damage-associated molecular patterns (DAMPs) that arise from cell stress, damage, or death (infection independent). Due to their role in a non-pathological tissue response, we believe surface treatment of implants with DAMP molecules can greatly diminish fibrotic bioimplant response and can even counteract the signaling of more inflammatory PAMP molecules. We have invented a biomaterial platform with highly tunable surface chemistry (to allow DAMP attachment) and an extremely low inherent fibrotic biomaterial response called Microporous Annealed Particle (MAP) scaffolding. We will use a murine model of injection-implant of the MAP scaffolding to identify DAMPs that instruct productive wound healing and/or limit the negative consequences PAMP-mediated biomaterial rejection. This will have important consequences for our understanding of the wound healing environment and represent proof of principle experiments for a tool that can be harnessed to improve wound healing, induce scar remodeling, and limit negative immune responses at bioimplant sites.

Public Health Relevance

A negative immune response causes both biomaterial implant rejection and pathological wound healing associated with scar formation leading to impaired tissue function. This project uses a novel tool to identify immune signaling molecules that 1) promote a productive wound healing response and 2) limit inflammatory responses signaled by microbial contaminants common to surgery rooms. These tools have the potential to improve wound healing, induce remodeling of developing scars, and reduce bioimplant rejection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21EB028971-01A1
Application #
10057727
Study Section
Biomaterials and Biointerfaces Study Section (BMBI)
Program Officer
Russell, Luisa Marie
Project Start
2020-08-01
Project End
2023-04-30
Budget Start
2020-08-01
Budget End
2021-04-30
Support Year
1
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Virginia
Department
Biomedical Engineering
Type
Biomed Engr/Col Engr/Engr Sta
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904